syl-1001
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
3
Phase 4
0
Earliest trial started Jul 1, 2011 (NCT01438281)
Timeline
Indications
Mechanism of action
- Vanilloid receptorANTAGONIST
TRPV1 antagonist
Small interfering RNA (siRNA).
- TRPV1 mRNAANTISENSE INHIBITOR
Vanilloid receptor mRNA antisense inhibitor
Small interfering RNA (siRNA).
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3707356 ↗
Also known as
- syl1001
- syl-1001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05310422 | Phase 3 | Mar 24, 2022 | PharmaMar |
| NCT04819269 | Phase 3 | May 25, 2021 | PharmaMar |
| NCT03108664 | Phase 3 | May 18, 2017 | PharmaMar |
| NCT02455999 | Phase 2 | Jun 1, 2015 | PharmaMar |
| NCT01776658 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2012 | PharmaMar |
| NCT01438281 | Phase 1 | Jul 1, 2011 | Clinica Universidad de Navarra, PharmaMar |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PharmaMar | For profit | 6 | 6 | 3 | 2011 |
| Clinica Universidad de Navarra | Academic/Hospital | 1 | 0 | 1 | 2011 |
2 organizations
Page 1 / 1